

May 15, 2008

ADVISORY TO HEALTHCARE PROVIDERS AND DISPENSERS

Dear Health Care Professional:

On May 6, 2008, a transport trailer containing product in transit from the JOM Pharmaceutical Services, Inc. Distribution Center in Kentucky to one of our specialty distributors was stolen. The stolen product has not been recovered. The trailer contained a shipment of refrigerated products, including REMICADE[®] (infliximab), PROCRIT[®] (epoetin alfa), and DOXIL[®] (doxorubicin HCl liposome injection). The amounts stolen are relatively small compared to the total lot sizes distributed. The details of the stolen shipment are listed below.

NDC	Description	Lot Number	Expiration Date
59676-3100-1	Cartons containing six (6) single dose vials of PROCRIT [®] (epoetin alfa) 10,000 U/mL	D091534	07/2010
59676-3200-4	Cartons containing four (4) multidose vials of PROCRIT [®] (epoetin alfa) 20,000 U/mL	P113612	09/2010
59676-3400-1	Cartons containing four (4) single dose vials of PROCRIT [®] (epoetin alfa) 40,000 U/mL	P106803	06/2010
17314-9600-1	Cartons containing 1 DOXIL [®] (doxorubicin HCl liposome injection) 20mg in 10mL (2 mg/mL) single use vial.	0717124	03/2009
17314-9600-2	DOXIL [®] (doxorubicin HCl liposome injection) 50mg in 25mL (2 mg/mL) single use vial	0715423	02/2009
57894-0300-1	Cartons containing one (1) vial of REMICADE [®] (infliximab) 100mg	8AM26021P1	01/2011
57894-0300-1	Cartons containing one (1) vial of REMICADE [®] (infliximab) 100mg	8BK35014P1	02/2011

As always, our immediate objective is to take appropriate steps for patient safety and the integrity of the products they receive. To that end, we discontinued distribution on May 7, 2008 of the lots with the same lot numbers as the stolen product. In order to minimize confusion, we are also voluntarily withdrawing the remaining product with the same lot numbers from the wholesalers and specialty distributors in order to isolate the lot numbers, which will make it easier to identify stolen product should it re-enter the supply chain. Please continue to purchase product only through your Authorized Distributors. The list of authorized distributors for our pharmaceutical products can be viewed on our website, www.jom.com. It is important to note that all product received from Authorized Distributors prior to the date of this letter should not be impacted and continues to be safe for use. In addition, please note that this withdrawal only applies to the lots identified above, and you can continue to receive product from other lots through your Authorized Distributors.

In 2003, JOM, the distribution organization for all Johnson & Johnson pharmaceutical products, including Centocor, Inc. and Ortho Biotech Products, L.P., implemented an Authorized Distributor policy. This policy was put in place to prevent the possible re-entry of counterfeit, diverted, mishandled or repackaged pharmaceutical products into the market place. To be considered one of our Authorized Distributors in the U.S. and Puerto Rico, distributors must commit to only sourcing products directly from JOM and must agree to be audited to confirm their compliance with this policy.

Before dispensing our pharmaceutical products to your patients, it is important to ensure that you have purchased those products solely from JOM Authorized Distributors. Sourcing from the secondary market can pose many uncertainties with regard to the safety and integrity of our products as they flow through the supply chain.

If you have purchased REMICADE, PROCRIT, or DOXIL from an Authorized Distributor, based upon the policies in place, the safety and security of the product should be intact. All three of these products have tamper-evident features that can be used to authenticate the package. You may contact the number below to assist you with the authentication of these features. However, if you are uncomfortable utilizing product with the same lot numbers as the stolen product, we will certainly accept a return of the product at full credit.

Should you have any information about the recent incident under investigation, or have any additional questions, we would appreciate and encourage you to contact us at Centocor Ortho Biotech Medical Information (888) 626-5660.

Please see Important Safety Information for REMICADE[®] (infliximab), PROCRIT[®] (epoetin alfa), and DOXIL[®] (doxorubicin HCl liposome injection) at their respective websites.



John Dempsey
Vice President
Strategic Customer Group
Centocor Ortho Biotech Services, LLC